【摘要】 目的 探讨不同回声类型超声造影剂在胃肠疾病诊断中的价值。 方法 采用“胃窗声学造影剂”充盈检查法，用凸阵3.5 MHz探头，对2009年3-8月366名受检者行经腹壁超声检查。受检者随机分为两组：饮水者为A组，饮有回声造影剂者为B组。 结果 选择性地应用合适的造影剂，能有效地提高对胃肠疾病的超声诊断水平。【Abstract】 Objective To evaluate the application of contrast agents with different echogenic in the diseases of stomach and intestine. Methods Totally, 366 patients were included in the study from March to August 2009. Patients were randomly divided into two groups： group A (oral acoustic contrast agent) and group B (water). Contrast-enhanced Doppler sonography was performed with 3.5 MHz abdomen probe. Results Contrast agent with anechoic was good for showing iso-echoic and hyperechoic tissue.Hyperechoic contrast agent was better for showing hypoechoic changes according to its long sitting-time in stomach. Conclusion Contrast enhanced ultrasound has practical value in diagnosis of the diseases of stomach and intestine.
ObjectivesTo investigate the efficacy and safety of Hou Gu Mi Xi (HGMX) in patients with nonorganic gastrointestinal disorders (NOGD) from the aspect of dietary therapy.MethodsA randomized, double-blind, parallel, placebo-controlled trial was performed. Patients with NOGD and spleen qi deficiency (SQD) syndrome were randomly assigned into HGMX or placebo group. Each received 30 g/day HGMX or placebo for one year. The outcomes included SQD scores, body weight, body mass index (BMI), gastrin-17, and adverse events (AEs) between HGMX and placebo groups, or subgroups divided by NOGD type or helicobacter pylori (Hp) infection, at the 0th, 2nd, 4th, 8th, 26th, or 52nd weeks’ follow-up.ResultsThe reduction of SQD scale score was found in the HGMX group compared with the placebo group at 4th week (MD=−9.40, 95%CI −18.53 to −0.27, P=0.044), 8th week (MD=−10.07, 95%CI −19.66 to −0.48, P=0.04), 26th week (MD=−12.45, 95%CI −22.31 to −2.59, P=0.014) and 52th week (MD=−17.25, 95%CI −28.53 to −5.97, P=0.003), respectively. In the subgroup analyses, HGMX showed significant efficacy in Hp-negative patients with the detailed reduction of SQD scale score being (MD=−15.20, 95%CI −28.16 to −2.24, P=0.022), (MD=−17.91, 95%CI −31.22 to −4.59, P=0.009) and (MD=−20.38, 95%CI −35.43 to −5.32, P=0.008) at the 8th, 26th and 52nd week, respectively, and in patients with chronic nonatrophic gastritis with the detailed reduction being (MD=−13.02, 95%CI −24.75 to −1.29, P=0.03), (MD=−12.43, 95%CI −24.36 to −0.5, P=0.041) and (MD=−15.90, 95%CI −30.72 to −1.08, P=0.036) at the 2nd, 26th and 52nd week, respectively, and in patients with functional gastrointestinal disease with the reduction being (MD=−18.22, 95%CI −35.75 to −0.69, P=0.042) at the 52nd week. However, no significant efficacy was found in Hp-positive patient at any time. HGMX was not associated with changes in weight, BMI, or gastrin-17. No AEs were reported in the HGMX group.ConclusionsHGMX improves SQD symptoms in patients with NOGD, especially Hp-negative patients, and has a good safety profile.